Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.

ABSTRACT: Infants with MLL-rearranged infant acute lymphoblastic leukemia (MLL-r iALL) undergo intense therapy to counter a highly aggressive malignancy with survival rates of only 30-40%. The majority of patients initially show therapy response, but in two-thirds of cases the leukemia returns, typically during treatment. The glucocorticoid drug prednisone is established as a major player in the treatment of leukemia and the in vivo response to prednisone monotreatment is currently the best indicator of risk for MLL-r iALL. We used two different single-cell RNA sequencing technologies to analyze the expression of a prednisone-dependent signature, derived from an independent study, in diagnostic bone marrow and peripheral blood biopsies. This allowed us to classify individual leukemic cells as either

SUBMITTER: Candelli T 

PROVIDER: S-EPMC8727302 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature